Rubicon Research Limited has announced a postal ballot process to seek shareholder approval for two significant appointments, as communicated to BSE Limited and National Stock Exchange of India Limited on February 13, 2026.

Proposed Resolutions

The company has outlined two key resolutions for shareholder consideration:

E-Voting Schedule

The postal ballot will be conducted exclusively through remote e-voting, with the following timeline:

Independent Director Appointment

Dr. Pradnya Saravade, a former Indian Police Service officer with extensive governance experience, has been proposed for appointment as an Independent Woman Director. Her appointment would be effective from February 03, 2026, to February 02, 2029, for a term of three consecutive years.

Dr. Saravade brings significant expertise in:

• Strategic leadership and sector expertise
• Governance and risk management
• Ethics management
• Stakeholder relations and grievance redressal
• ESG and social impact initiatives
• People management

Her professional background includes leadership roles at Maharashtra Railway Police, Securities and Exchange Board of India (SEBI), Central Bureau of Investigation (CBI), and Mumbai Police. She holds MBBS and MS (General Surgery) degrees from Grant Medical College, Mumbai.

Secretarial Auditor Appointment

M/s. BNP & Associates, Company Secretaries, has been recommended for appointment as the company's Secretarial Auditors for the financial year 2025-26. The firm holds Firm Registration Number P2014MH037400 and Peer Review No. 7353/2025.

The appointment details include:

Voting Process

In compliance with Ministry of Corporate Affairs circulars, the postal ballot notice is being sent electronically to shareholders whose email addresses are registered with the company's Registrar and Share Transfer Agent, MUFG Intime India Private Limited, and the depositories NSDL and CDSL.

Shareholders can access the e-voting facility through multiple channels:

• Company website: www.rubicon.co.in
• MUFG Intime platform: https://instavote.linkintime.co.in
• Stock exchange websites (BSE and NSE)
• Depository websites (NSDL and CDSL)

The company has appointed Mr. Gaurav Sainani and Mr. Sunny Gogiya, Partners at M/s. S/GGS and Associates, Company Secretaries, as Scrutinizers for the postal ballot process. The voting rights of members will be proportionate to their shareholding in the paid-up equity share capital as on the cut-off date.

Rubicon Research Limited has submitted its Q3 FY26 earnings conference call transcript to stock exchanges, revealing strong financial performance and management's optimistic outlook for future growth.

Strong Q3 FY26 Financial Performance

The company delivered robust financial results for the quarter ended December 31, 2025, with significant year-over-year improvements across key metrics.

Nine-Month Performance Highlights

For the nine months ended December 31, 2025, the company maintained strong momentum with revenue reaching ₹1,240 crores, up 34% year-over-year.

R&D Investment and Future Growth Strategy

CEO Parag Sancheti emphasized the company's strong R&D-driven growth model during the February 3, 2026 earnings call. The company maintained R&D expenses at ₹52 crores for the quarter, representing 11% of revenue, in line with guidance of 10%-11%.

Sagar Oak, Senior Vice President of Corporate Development and Strategy, presented compelling data showing improving R&D productivity. The analysis revealed that R&D investment returns have increased from 3.3x to 5.7x over rolling three-year periods, demonstrating enhanced efficiency in product development and commercialization.

Pithampur Facility Expansion

The company is progressing with operationalizing its newly acquired Pithampur manufacturing facility, expected to be validated by mid-2026 with commercialization beginning in Q1 CY'27. This facility will provide capabilities for high potent oncology, hormones, and steroids production.

Specialty Products Growth

The specialty portfolio continues to strengthen, contributing 31%-32% of gross profit in Q2 and Q3, higher than the 26.9% contribution in full year FY25. Management highlighted successful launches including Fluticasone, where the company became the third to receive approval since 2007.

Management Guidance and Outlook

CFO Nitin Jajodia reaffirmed the company's commitment to maintaining operating EBITDA margins in the 22%-23% range despite temporary gross margin pressure from increased outsourcing to meet higher-than-expected demand. The company expects to invest over ₹500 crores in R&D across fiscals 2026, 2027, and Q1 2028, supporting continued revenue growth visibility through FY30.

The earnings call transcript was submitted to BSE and NSE on February 6, 2026, by Company Secretary Deepakshree Tanksale, maintaining regulatory compliance under SEBI listing requirements.